Research programme: scleroderma therapeutics - BioFocus/Biogen
Latest Information Update: 09 Apr 2015
At a glance
- Originator BioFocus DPI
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Scleroderma
Most Recent Events
- 31 Mar 2014 BioFocus has been acquired by Charles River Laboratories
- 12 Nov 2013 Early research in Scleroderma in United Kingdom (unspecified route)